Suven Life Sciences has announced the date for their Annual General Meeting in August 2026. The company's financials for FY26 have been approved. A fine imposed by BSE has been waived, but a decision regarding a waiver from NSE is still pending. The board encourages compliance and further discussions.

Suven Life Sciences has made significant progress in its Masupirdine trial, with 76% of participants now enrolled for the potential Alzheimer's and dementia treatment. The company is moving closer to completing this Phase 3 study.

Suven Life Sciences will release their audited Q4 and FY2026 financial results on May 13, 2026. Trading activity for the company is suspended from May 13 to May 15, 2026, following the announcement of the results.